Trade

with

TherapeuticsMD Inc
(Amex: TXMD)
AdChoices
4.22
+0.30
+7.53%
After Hours :
-
-
-

Open

4.20

Previous Close

3.92

Volume (Avg)

1.99k (1.43M)

Day's Range

4.20-4.22

52Wk Range

2.03-9.01

Market Cap.

-

Dividend Rate ( Yield )

-

Beta

0.81

Shares Outstanding

155.81M

P/E Ratio (EPS)

-

AdChoices
Fundamentals
  • Key statistics
  • Growth
  • Profitability
  • Financial health
  • Price ratios
  • Trading statistics
  • Management effectiveness
Industry Drug Manufacturers – Major
Highlights
Analyst Recommendation: Not Available
    • Revenue

    • 8.78M

    • Net Income

    • -28.42M

    • Market Cap.

    • -

    • Enterprise Value

    • -

    • Net Profit Margin %

    • -307.64

    • PEG (Price/Earnings Growth) Ratio

    • -

    • Beta

    • 0.81

    • Forward P/E

    • -

    • Price/Sales

    • 51.02

    • Price/Book Value

    • 17.57

    • Price/Cash flow

    • -19.49

      • EBITDA

      • -25.69M

      • Return on Capital %

      • -82.56

      • Return on Equity %

      • -95.11

      • Return on Assets %

      • -82.56

      • Book Value/Share

      • 0.24

      • Shares Outstanding

      • 155.81M

      • Last Split Factor (Date)

      • -

      • Last Dividend (Ex-Date)

      • -

      • Dividend Declaration Date

      • -

      Analyst Recommendation
      -
      Not Available
        • 1 Year Price Target

        • -

        • Credit Rating

        • -

        • Analysts

        • 0

        • EPS Estimate

        • -

        • Cashflow Estimate

        • -

        Morningstar Consensus estimate data
        • Growth Rate (%)

        • Company

        • Industry

          • Sales (Revenue)

            Q/Q (last year)

          • 80.30

          • 0.89

          • Net Income

            YTD/YTD (last year)

          • -

          • 7.80

          • Net Income

            Q/Q (last year)

          • -

          • 4.50

          • Sales (Revenue)

            5-Year Annual Average

          • -

          • 6.10

          • Net Income

            5-Year Annual Average

          • -

          • 3.73

          • Dividends

            5-Year Annual Average

          • -

          • 2.17

          • Profit Margins (%)

          • Company

          • Industry

            • Gross Margin

            • 75.81

            • 69.92

            • Pre-Tax Margin

            • -307.64

            • 21.84

            • Net Profit Margin

            • -307.64

            • 18.37

            • Average Gross Margin

              5-Year Annual Average

            • 49.60

            • 71.90

            • Average Pre-Tax Margin

              5-Year Annual Average

            • -3,714.90

            • 21.92

            • Average Net Profit Margin

              5-Year Annual Average

            • -3,791.80

            • 903.40B

            • Financial Ratios

            • Company

            • Industry

              • Debt/Equity Ratio

              • -

              • 0.32

              • Current Ratio

              • 6.02

              • 1.92

              • Quick Ratio

              • 5.47

              • 1.31

              • Interest Coverage

              • -31.71

              • 17.64

              • Leverage Ratio

              • 1.19

              • 2.03

              • Book Value/Share

              • 0.24

              • 14.62

              • Price Ratios

              • Company

              • Industry

                • Current P/E Ratio

                • -15.58

                • 22.62

                • P/E Ratio 5-Year High

                • -628.03

                • 193.96

                • P/E Ratio 5-Year Low

                • -1.96

                • 87.26

                • Price/Sales Ratio

                • 47.85

                • 3.79

                • Price/Book Value

                • 16.50

                • 3.78

                • Price/Cash Flow Ratio

                • -19.49

                • 14.31

                • Key Metrics

                • Company

                  • Shares Short

                    as of -

                  • -

                  • Short Ratio

                    as of -

                  • -

                  • Short % of Float

                    as of -

                  • -

                  • Shares Short

                    prior month

                  • -

                  • Trailing Annual Dividend Yield

                  • -

                  • 5 Year Average Dividend Yield

                  • -

                  • Key Metrics

                  • Company

                    • Payout Ratio

                    • -

                    • Dividend Date

                    • -

                    • Ex-Dividend Date

                    • -

                    • Last Split Factor

                      new per old

                    • -

                    • Last Split Date

                    • -

                    • Key Metrics

                    • Company

                    • Industry

                      • Return on Equity %

                        (5-Year Average)

                      • -95.11

                        (-)

                      • 17.42

                        (18.66)

                      • Return on Assets %

                        (5-Year Average)

                      • -82.56

                        (-575.60)

                      • 8.45

                        (8.77)

                      • Return on Capital %

                        (5-Year Average)

                      • -92.20

                        (-)

                      • 12.41

                        (13.18)

                      • Income/Employee

                      • -

                      • 90.07k

                      • Inventory Turnover

                      • 1.92

                      • 2.46

                      • Asset Turnover

                      • 0.27

                      • 0.46

                      Current Historical
                      Financials
                      • Income Statement
                      • Balance Sheet
                      • Cash Flow
                      Operating Income
                      -25.81M
                      Operating Margin
                      -294.09
                      Total Equity
                      -
                      Retained Earnings
                      -
                      Free Cashflow
                      -
                      Price/Cashflow
                      -19.49
                      Ownership

                      Institutional Ownership

                      59.17%

                      Top 10 Institutions

                      50.36%

                      Mutual Fund Ownership

                      38.62%

                      Float

                      61.96%

                      5% / Insider Ownership

                      18.05%

                      Corporate insiders or major stockholders reporting trading activity in the stock.

                      Top Mutual Fund Owners

                      Top Institutional Owners

                      Mutual Fund Name

                      Institution Name

                      • Mutual Fund Name

                      • Shares Held

                      • % Change

                      • % Outstanding

                      • Fidelity® Puritan® Fund

                      •  

                        5,996,914

                      • 0.00

                      • 3.85

                      • Fidelity® Select Biotechnology Portfolio

                      •  

                        5,215,907

                      • 0.00

                      • 3.35

                      • Dreyfus Opportunistic Small Cap Fund

                      •  

                        4,775,884

                      • 0.00

                      • 3.07

                      • Hartford Capital Appreciation HLS Fund

                      •  

                        4,480,119

                      • 0.00

                      • 2.88

                      • Fidelity® Select Health Care Portfolio

                      •  

                        3,000,000

                      • 0.00

                      • 1.93

                      • SPDR® S&P Pharmaceuticals ETF

                      •  

                        2,857,067

                      • 0.00

                      • 1.55

                      • MFS® New Discovery Fund

                      •  

                        2,687,383

                      • 0.12

                      • 1.72

                      • Vanguard Capital Value Fund

                      •  

                        2,415,071

                      • 0.00

                      • 1.65

                      • Franklin Biotechnology Discovery

                      •  

                        2,356,782

                      • 10.07

                      • 1.62

                      • iShares Russell 2000 (AU)

                      •  

                        1,625,145

                      • -1.81

                      • 0.88

                      • Institution Name

                      • Shares Held

                      • % Change

                      • % Outstanding

                      • Wellington Management Company, LLP

                      •  

                        20,361,541

                      • +0.31%

                      • 13.95

                      • Fidelity Management and Research Company

                      •  

                        16,694,039

                      • +13.02%

                      • 11.44

                      • Boston Co Asset Management LLC

                      •  

                        6,557,840

                      • +88.53%

                      • 4.49

                      • Gilder Gagnon Howe & CO LLC

                      •  

                        6,136,366

                      • -0.35%

                      • 4.21

                      • MFS Investment Management K.K.

                      •  

                        4,915,440

                      • +12.28%

                      • 3.37

                      • Dreyfus Corporation

                      •  

                        4,775,884

                      • 0.00%

                      • 3.07

                      • RA Capital Management, LLC

                      •  

                        4,303,066

                      • -56.26%

                      • 2.95

                      • Franklin Advisers, Inc.

                      •  

                        3,642,382

                      • 0.00%

                      • 2.50

                      • BlackRock Fund Advisors

                      •  

                        3,574,126

                      • +13.86%

                      • 2.45

                      • Vanguard Group, Inc.

                      •  

                        2,813,966

                      • +5.82%

                      • 1.93

                      Company Profile

                      Sector

                      Healthcare

                      Industry

                      Drug Manufacturers – Major

                      Type

                      Distressed

                      Style

                      Small Growth

                      TherapeuticsMD Inc was incorporated in Utah in 1907 under the name Croff Mining Company. The Company redomicile itself in the state of Nevada. It is a women’s health care product company focused on creating and commercializing produc...morets exclusively for women. The Company conducts clinical trials necessary for regulatory approval and commercialization of advanced hormone therapy pharmaceutical products. The drug candidates used in its clinical trials are designed to alleviate the symptoms of and reduce the health risks resulting from menopause-related hormone deficiencies, including hot flashes, osteoporosis, and vaginal dryness. In addition, the Company manufactures and distributes branded and generic prescription prenatal vitamins, as well as over-the-counter, or OTC, cosmetics and vitamins. The Com...morepany’s hormone therapy drug candidates include TX 12-001HR, TX 12-002HR, TX 12-003HR and TX 12-004HR. TX 12-001HR combination estradiol and progesterone drug candidate, is undergoing clinical trials for the treatment of moderate to severe vasomotor symptoms due to menopause, including hot flashes, sleep disturbances, night sweats and vaginal dryness, for post-menopausal women with an intact uterus. TX 12-002HR is a natural progesterone formulation for the treatment of secondary amenorrhea without the potentially allergenic component of peanut oil. TX 12-003HR is a natural estradiol formulation. This hormone therapy drug candidate would be chemically identical to the hormones that naturally occur in a woman’s body. And, TX 12-004HR is a vaginal suppository estradiol drug candidate for the treatment of vulvar and vaginal atrophy, or VVA, in post-menopausal women with vaginal linings that do not receive enough estrogen. The Company offers a range of products targeted for women’s health specifically associated with pregnancy, nursing, child birth, post-child birth, and menopause, including prescription and over-the-counter prenatal vitamins, natural menopause relief products, iron supplements, vitamin D supplements and stretch mark creams under its vitaMedMD brand name and duplicate formulations of its prescription prenatal vitamin products, referred to as generic formulations, under its BocaGreenMD Prena1 name. The Company faces competition in a variety of areas, including developing and bringing new products to market before others, developing new technologies to improve existing products, developing new products to provide the same benefits as existing products at lower cost, and developing new products to provide benefits superior to those of existing products. It is subject to regulation under various state, local, and international laws that include provisions governing, among other things, the formulation, manufacturing, packaging, labeling, advertising, and distribution of dietary supplements and drugs.lessless

                      Key People

                      Mr. Robert G. Finizio

                      CEO/Director

                      The Honourable Governor Tommy G. Thompson

                      Chairman of the Board/Director

                      Mr. Daniel A. Cartwright

                      CFO/Chief Accounting Officer/Treasurer/Vice President, Divisional

                      Mr. Mitchell L. Krassan

                      Executive VP/Other Executive Officer

                      Mr. Jason Spitz

                      Vice President, Divisional

                      • TherapeuticsMD Inc

                      • 951 Broken Sound Parkway NW

                      • Boca Raton, FL 33487

                      • USA.Map

                      • Phone: +1 561 961-1900

                      • Fax: -

                      • therapeuticsmd.com

                      Incorporated

                      1907

                      Employees

                      69

                      Send Feedback

                      We appreciate your input!

                      • I'm having trouble signing into my Microsoft account

                      • I’m having problems with the services stripe (Mail, Facebook, etc.)

                      • There is an issue with my weather information

                      • I see an error in the content

                      • Other

                      Please give an overall site rating: